{
 "id": "pulmonary-arterial-hypertension",
 "name": "Pulmonary Arterial Hypertension",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "cardiovascular",
 "parent": "pulmonary hypertension",
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Pulmonary Arterial Hypertension",
   "organization": "Good Days",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed).",
   "readOn": "2026-11-08",
   "source": "https://mygooddays.org/patients/diseases-covered/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Macitentan",
   "pages": [
    {
     "brand": "Opsumit",
     "url": "https://omnirx.org/medicines/opsumit"
    }
   ],
   "labelSentence": "OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Riociguat",
   "pages": [
    {
     "brand": "Adempas",
     "url": "https://omnirx.org/medicines/adempas"
    }
   ],
   "labelSentence": "Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Bayer US Patient Assistance Foundation",
     "url": "https://www.patientassistance.bayer.us/en/about/bayer-products",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Bayer prescription medicines included in the program",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Selexipag",
   "pages": [
    {
     "brand": "Uptravi",
     "url": "https://omnirx.org/medicines/uptravi"
    }
   ],
   "labelSentence": "UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Sotatercept-Csrk",
   "pages": [
    {
     "brand": "Winrevair",
     "url": "https://omnirx.org/medicines/winrevair"
    }
   ],
   "labelSentence": "WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2221693ee2-cd23-4137-ac67-066bb3a4a9b7%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Merck Patient Assistance Program",
     "url": "https://omnirx.org/assistance/merck-helps",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Products: participating products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Treprostinil",
   "pages": [
    {
     "brand": "Tyvaso Dpi",
     "url": "https://omnirx.org/medicines/tyvaso-dpi"
    }
   ],
   "labelSentence": "Treatment of pulmonary arterial hypertension (PAH;",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2233050ee2-519b-1f0b-d4df-9e14dd329c57%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}